Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Publication Name: Annals of Oncology

Author(s): A. Goldhirsch, W. C. Wood, A. S. Coates, R. D. Gelber, B. Thu¨ rlimann, H.-J. Senn & Panel

The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel adopted a new approach to the classification of patients for therapeutic purposes based on the recognition of intrinsic biological subtypes within the breast cancer spectrum. For practical purposes, these … Continued

Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer

Publication Name: European Journal of Cancer

Author(s): Valesca Retel, MA Joore, WH van Harten

Background: The 70-gene signature (MammaPrint) is a prognostic test used to guide adjuvant treatment decisions in patients with node-negative breast cancer. In order to decide upon its use, a systematic comparative analysis of the effects of the 70-gene signature,the Saint … Continued

Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer.

Publication Name: Annals of Oncology

Author(s): Goldhirsch A, Ingle JN, Gelber RD et al.

The 11th St Gallen (Switzerland) expert consensus meeting on the primary treatment of early breast cancer in March 2009 maintained an emphasis on targeting adjuvant systemic therapies according to subgroups defined by predictive markers. Any positive level of estrogen receptor … Continued